Preclinical studies indicate that SOT106 (anti-LRRC15 ADC) is highly effective and well-tolerated with significant promise for treating sarcomas and potentially other LRRC15-positive malignancies IND filing anticipated in Q4 2026 Program advancing towards clinical readiness and exploring partnering opportunities SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results supporting the development of SOT106, its antibody-drug...
SOTIO Biotech
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with SOTIO
Contact SOTIO, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack